KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) (NCT07406633)
A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
🩺 Plain-English Summary (8th-Grade Level)
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.
Who can join: Review the eligibility criteria below.
Location: USC Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
- University of Chicago Medical Center — Chicago, Illinois
- University of Iowa Health Care — Iowa City, Iowa
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Michigan Hospitals — Ann Arbor, Michigan
- Mayo Clinic - Rochester — Rochester, Minnesota
- Northwell Health/R.J. Zuckerberg Cancer Center — Lake Success, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Oregon Health & Science University — Portland, Oregon
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- UT MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (858) 214-2700
Email: kumquatstudies@kumquatbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All GIST - Gastrointestinal Stromal Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.